Thank you for subscribing!
Finfeed Archived Feb 23, 2018
Merck & Co (NYSE:MRK), one of the largest pharmaceutical companies in the world, has bid A$502 million for ASX-listed Viralytics (ASX:VLA) — a deal that would secure the rights to VLA’s lead immunotherapy cancer drug, Cavatak.
Finfeed Archived Feb 02, 2018
Biotech play BARD1 Life Sciences Limited (ASX:BD1) today announced that it has received a Japanese patent for its BARD1 isoforms.
Finfeed Archived Jan 10, 2018
BARD1 Life Sciences Limited (ASX:BD1) has received positive results from its OC-400 Study that showed BARD1-Ovarian achieved high accuracy for detection of ovarian cancer.
Finfeed Archived Oct 03, 2017
While a diagnosis of cancer is still likely to strike fear into the heart of any patient and their loved ones, treatments for the horrible disease are progressing – and for many cancers, survival rates are steadily heading in the right direction.
Get expert stock analysis direct in your inbox
Finfeed Archived Sep 26, 2017
MitchelLake’s Robin Block spoke with Leslie Chong, the CEO of Imugene, to find out how technology is changing biotech, and how it is transforming the general understanding of cancer treatment.
Next Investors Archived Aug 09, 2017
It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.
Finfeed Archived Aug 07, 2017
BARD1 Life Sciences (ASX: BD1), a company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer, has gained patent approval from IP Australia for its “BARD1 isoforms in lung and colorectal cancer and use thereof”.
Finfeed Archived Jul 31, 2017
Until now, a one off treatment of Opdivo would cost A$5,000, or over A$100,000 per year. Thanks to the Federal Government, it will now be available for just A$38.80 per treatment, or A$6.30 with a concession card.
Finfeed Archived Jun 16, 2017
Shares in cancer immunotherapy drug developer, Imugene (ASX: IMU) rallied more than 7% on Thursday while the S&P/ASX All Ordinaries index plunged 65.5 points or 1.1%.
Join Our Mailing List
